. 2020 Sep 21;64(10):e00398-20. doi: 10.1128/AAC.00398-20

TABLE 3.

MIC of meropenem in combination with vaborbactam against P. aeruginosa expressing KPC-2 W105 mutants

Enzyme mutation	Vaborbactam concn (μg/ml)								PV₅₀^a (μg/ml)	Decrease in MIC^b
Enzyme mutation	0	0.16	0.31	0.63	1.25	2.5	5	10	PV₅₀^a (μg/ml)	Decrease in MIC^b
WT	32	32	16	2	0.25	0.063	0.063	≤0.031	0.73 ± 0.02	128
W105F	32	16	8	1	0.125	0.063	≤0.031	≤0.031	0.65 ± 0.11	256
W105N	16	8	4	1	0.25	0.063	0.063	≤0.031	0.65 ± 0.01	64
W105L	8	8	4	2	0.5	0.125	0.063	≤0.031	1.06 ± 0.11	16
W105V	8	4	4	1	0.25	0.125	0.063	≤0.031	0.87 ± 0.11	16
W105D	32	16	8	4	2	0.5	0.125	≤0.031	1.49 ± 0.09	16
W105A	8	8	4	2	0.25	0.125	≤0.031	≤0.031	0.87 ± 0.1	32
W105Y	32	16	8	2	0.25	≤0.031	≤0.031	≤0.031	0.68 ± 0.05	128
W105S	8	8	4	2	0.25	0.125	≤0.031	≤0.031	1.00 ± 0.02	32

Data are averages of three measurements. Differences from the WT are statistically significant (P < 0.05) for W105D, W105L, and W105S.

Fold decrease in meropenem MIC with vaborbactam at 1.25 μg/ml.